Thalidomide combined with endoscopy in the treatment of Cronkhite-Canada syndrome: A case report

Jia-Mei Rong, Meng-Lin Shi, Jun-Kun Niu, Juan Luo, Ying-Lei Miao

Jia-Mei Rong, Meng-Lin Shi, Jun-Kun Niu, Juan Luo, Ying-Lei Miao, Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China

Corresponding author: Ying-Lei Miao, PhD, Chief Physician, Department of Gastroenterology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming 650032, Yunnan Province, China. miaoyinglei@kmmu.edu.cn

Abstract

BACKGROUND
Cronkhite-Canada syndrome (CCS) is a rare non-hereditary disease with a poor prognosis and a mortality rate of up to 55%. Currently, there is no standard treatment for CCS. The department of gastroenterology of our hospital admitted a patient with CCS whose symptoms improved significantly after treatment with thalidomide combined with endoscopy, and there was no obvious adverse reaction during the 2-year follow-up.

CASE SUMMARY
A 47-year-old Chinese man presented with diarrhea for more than 4 mo, accompanied by loss of taste, fatigue, and weight loss. Physical examination demonstrated that the patient’s skin and hands were hyperpigmented, the front edges of the nails of both hands were notably thickened and yellow, and the nails were partially atrophied. Gastrointestinal endoscopy identified a diffuse polypoid bulge, and the patient bore an albumin level of 27.3 g/L. The level of the calcium correction amount was (2.164 mM) which allowed for a comprehensive diagnosis of Cronkhite-Canada syndrome, combined with hypoalbuminemia and hypocalcemia. Thalidomide of 150 mg per day was administered to regulate immunity, and the symptoms were relieved after 1 wk. During the follow-up period, polyps were still found that had not been resolved by thalidomide treatment, and endoscopic therapy was performed. This resulted in further improvement of his condition and no particular discomfort during the 2 years of follow-up.

CONCLUSION
The patient’s symptoms were significantly relieved by thalidomide 2 years after treatment, proposing it as a potential treatment for CCS.

Key Words: Cronkhite-Canada syndrome; Diarrhea; Polyp; Thalidomide; Endoscopic therapy; Case report
Core Tip: Cronkhite-Canada syndrome (CCS) is a rare non-hereditary disease with a poor prognosis and a mortality rate of up to 55%. Currently, there is no standard treatment for CCS. The symptoms of the patient in this case were significantly improved after treatment with thalidomide combined with endoscopy, and they were followed up for 2 years. No obvious adverse reactions were observed. Thalidomide may be a new potential therapeutic drug for CCS, and we will continue to follow up to determine its long-term efficacy.

INTRODUCTION

Cronkhite-Canada syndrome (CCS), also known as polyp pigmentation alopecia fingernail dystrophy syndrome, is characterized by multiple polyps of the gastrointestinal tract, hair loss, nail dystrophy, and abnormal skin pigmentation. It was first reported by Cronkhite and Canada in 1955[1]. The pathogenesis and etiology of CCS remain unclear and may be related to infection, autoimmunity, vitamin deficiency, mental stress, or fatigue[2]. CCS is a rare disease with a prevalence rate of 3.7 per million[3]. Since the disease was first reported in 1955, only about 500 cases have been reported in the world, of which 75% are from Japan[4]. The first symptoms in most patients are gastrointestinal, often accompanied by anemia, edema, and weight and taste loss[5]. At present, the etiology, pathogenesis, and reasonable treatment of CCS disease are still in the exploratory stage. This study reports the clinical data, diagnosis, and treatment of a case of CCS in our hospital with thalidomide combined with endoscopy. It also reviews the relevant literature and summarizes the current treatment of CCS so as to provide clinicians with a treatment reference for patients with CCS.

CASE PRESENTATION

Chief complaints
A 47-year-old male patient presented with diarrhea for more than four months.

History of present illness
The patient had diarrhea without obvious incentives for more than 4 mo. The number of times a day was 8-10, and the stool was yellow paste. The amount was approximately 100-200 mL/time. There was no mucus, pus, or blood and intermittent pain around the umbilical cord. The diarrhea was usually accompanied by loss of taste, fatigue, and occasional nausea and vomiting. The vomit included stomach contents, and there was no obvious abdominal distension or hair loss.

History of past illness
He had a previous medical history of hyperthyroidism, Grave’s eye disease, and diabetes mellitus.

Personal and family history
The patient smoked about 360 packs per year of cigarettes for more than 20 years and drank an average of 4 double liquors of alcohol per day for more than 10 years while denying any relevant family history.

Physical examination
On physical examination, the vital signs were as follows: body temperature, 36.3 ℃; blood pressure, 111/88 mmHg; heart rate, 110 beats per min; respiratory rate, 22 breaths per min. His height was 170 cm, and his weight was 75 kg. Furthermore, the skin around his lips and hands was pigmented, the anterior edge of the nails of both his hands was significantly thickened and yellow, and his nails were partially atrophied (Figure 1).

Laboratory examinations
Pertinent laboratory findings included an increased platelet count (5.01 × 10^11/L) and hypoalbuminemia.
Figure 1 Physical examination (March 16, 2020) revealed hyperpigmentation and nail atrophy in the patients. A: Lips and skin; B: Skin and fingernails; C: Skin and toenails.

Figure 2 A-C. Pathological examination of the tissue sent for gastric biopsy showed the existence of hyperplastic polyp changes. The colonoscopy performed identified mucus hyperemia, edema, and granular bulge in the lower segment of the ileum (about 30 cm away from the ileocecal valve), and a diffuse polypoid bulge of the mucosa could be observed from about 15 cm from the end of the ileum to the rectum, some of which was nodular with mucosal hyperemia and erosion on the surface. Rectal lesions were lighter than other intestinal segments (Figure 2D-F).

Figure 3. Pathological examination of the descending colon, transverse colon, ascending colon, terminal ileum, lower segment of the ileum, rectum, and sigmoid colon identified proliferative and juvenile polyps under the microscope.

FINAL DIAGNOSIS
The diagnosis of CCS was finally made.

TREATMENT
A thalidomide dose of 150 mg per day (two tablets each time, three times a day) was administered orally to regulate immunity, alongside enteral nutritional support to regulate the intestinal flora, stop the diarrhea, and ameliorate the remaining symptoms. After one week of treatment, the patients' diarrhea was relieved, and the taste loss, abnormal pigmentation, and malnourished nails were gradually improved. The patient continued the treatment after his discharge from the hospital.

OUTCOME AND FOLLOW-UP
At the first follow-up visit (July 1, 2020), the symptoms of fatigue, diarrhea, and taste loss were significantly improved, the pigmentation around the lips and the back of the hand had improved, and the nail development was close to normal (Figure 4A and B). He bore an albumin level of 38.8 g/L and a platelet count of $5.13 \times 10^{11}$/L. Gastroscopic examination revealed a diffuse polypoid protuberance of the mucosa of the whole stomach, pylorus, and duodenum and congestion of the surface mucosa (Figure 5A-C). During enteroscopic examination from the ileocecal part to the rectum, a diffuse polypoid protrusion of the mucosa could be observed, some of which was nodular, with congestion and erosion of surface mucosa. The rectal lesions were lighter than other intestinal segments. This examination showed a notable improvement as compared to the previous examination (Figure 6A-C).
Figure 2 Diffuse polypoid protrusion and congested surface mucosa and lower gastrointestinal endoscopy (March 30, 2020). Congestion of the whole colonic mucosa with edema, erosion, granular bulge, and partially nodular characteristics. A: Gastric antrum; B: Gastric body; C: Duodenum; D: Ileocecum; E: Ascending colon; F: Transverse colon.

Figure 3 Histopathological examination of lesions in the colon visualized by hematoxylin-eosin staining (March 30, 2020). The disease tests of polyps revealed hyperplastic and juvenile polyps. A: Terminal ileum; B: Transverse colon; C: Ectum. (A-C: Hematoxylin-eosin staining × 100).

At the second follow-up visit (October 28, 2020), the patient felt no discomfort, and the nails had returned to normal without pigmentation (Figure 4C and D). He bore an albumin concentration of 42.4 g/L and a platelet count of 3.35 × 10¹¹/L. Gastroscopic examination of the rough mucosa of the gastric fundus and body identified congestion and edema, and the same was true for the mucosa of the gastric horn, antrum, and duodenum. The lesion improved significantly (Figure 5D-F). Colonoscopy identified > 10 polyps with a diameter of about 0.3-1.0 cm, varying in size and shape throughout the large intestine, and with the remaining mucosa being smooth (Figure 6D-F). Thalidomide administration was adjusted to 100 mg per day (two tablets each time, two times a day) for treatment maintenance.

At the third follow-up visit (June 8, 2021), the patient felt no discomfort, and his nails had returned to normal without pigmentation. His albumin level was 47.1 g/L, and his platelet count was 2.46 × 10¹¹/L. Gastroscopic examination demonstrated congestion and edema of the gastric fundus, gastric body, gastric horn, gastric antrum, and duodenal mucosa. Colonoscopy identified > 10 polyps of different sizes and shapes with a diameter of about 0.3-1.0 cm throughout the whole large intestine. Since the larger polyps had not subsided after drug treatment and there was a risk of tumorigenesis, the polyps were removed by endoscopic high-frequency electrocoagulation. The pathological examination showed...
Physical examination identified that the pigmentation had subsided, and the nail growth was nearly normal. A: Lips and skin (July 1, 2020); B: Skin and fingernails (July 1, 2020); C: Lips and skin (October 28, 2020); D: Fingernails (October 28, 2020).

DISCUSSION

CCS is a rare and non-hereditary disease characterized by multiple polyps and ectodermal changes in the digestive tract. A retrospective study of 103 cases of CCS in China in 2020[6] found that the incidence rate of CCS among people aged 50-70 years was high (62.62%), most of them were men (72.82%), and 50 patients (51.02%) received corticosteroid treatment, which is the treatment most frequently deployed. The etiology and pathogenesis of CCS are not clear and may be related to diverse etiologies, such as immunity, infection, inflammation, lack of growth factors, arsenic poisoning, fatigue, stress response, or mental stress[7,8]. Increasing evidence supports autoimmune diseases as an underlying cause of CCS pathogenesis (Hashimoto’s thyroiditis, membranous nephropathy, rheumatoid arthritis, systemic lupus erythematosus[9]) accompanied by potentially increased levels of blood antinuclear antibody and IgG4. The typical characteristics of CCS include abdominal pain, diarrhea, hair loss, loss of finger or toenails, abnormal skin pigmentation, decreased libido and taste, weight loss due to insufficient food intake, malabsorption and gastrointestinal tract loss[10], hypoproteinemia, hypokalemia, and hypocalcemia, to name a few. Under endoscopy, it is often manifested by the presence of multiple polyps in the digestive tract below the esophagus. The diagnosis of CCS should be implemented comprehensively. At present, there is no unified diagnostic standard. Endoscopic features include diffuse polyps throughout the entire gastrointestinal tract, except for the esophagus. Pathological types of polyps in CCS mainly include inflammatory, hyperplastic, hamartomatous, and adenomatous polyps. Observed under the microscope, CCS polyps in different parts show some common features with relatively specific morphological manifestations, including edema and widening of the muscularis propria, inflammatory cell infiltration, local cystic expansion of glands, and filling
with proteins. Fluid or condensed mucus; even if normal mucosa is observed under endoscopy, biopsy often has abnormal manifestations, such as edema with a chronic inflammatory reaction, etc. Generally, when other gastrointestinal polyp syndromes are excluded and the patient presents typical endoscopic and histopathological manifestations, as well as gastrointestinal symptoms, such as diarrhea and ectodermal changes, CCS should be considered.

This case has been of an older man with chronic onset, mainly manifested by diarrhea, fatigue, decreased taste, and significant weight loss, with pigmentation around his lips and hands, as well as thickening and atrophy of his finger and toenails. The patient had a history of hyperthyroidism, Grave’s eye disease, and other diseases but bore no significant family history. His symptoms were accompanied by hypoalbuminemia and hypocalcemia. Gastroenteroscopy revealed diffuse mucosal polyp-like protuberances. The disease was diagnosed as proliferative polyps and tubular adenoma. After excluding familial genetic diseases with multiple intestinal polyps as main manifestations, such as familial adenomatous polyposis, Peutz-Jeghers syndrome, and other diseases, the diagnosis of CCS was comprehensively considered.

At present, there is no standard treatment for CCS, and few patients recover without treatment[11]. The currently used CCS treatments include glucocorticoids, antibiotics, 5-aminosalicylic acid, H2 receptor antagonists, calcineurin inhibitors, cyclosporine, azathioprine and anti-tumor necrosis factor antagonists, Helicobacter pylori eradication, fecal bacteria transplantation, nutritional support, and other symptomatic treatments[12-19]. Glucocorticoids are a commonly used treatment method that can quickly and effectively elicit disease remission. However, with the reduction or even withdrawal of glucocorticoids, some patients will relapse or even aggravate the disease. More than 35% of patients fail to achieve long-term clinical remission after taking glucocorticoids[20]. So far, there is no relevant report on thalidomide in the treatment of CCS.

Thalidomide is an effective tumor necrosis factor inhibitor with immunosuppressive, immunomodulatory, anti-inflammatory, and potentially anti-tumor activities[21]. It has been widely used in the clinic to treat autoimmune diseases, such as leprosy nodular erythema, vasculitis, ankylosing spondylitis, rheumatoid arthritis, Behcet’s disease, and inflammatory bowel disease[22-24]. Thalidomide can inhibit TNF-α transcription and the cytochrome pathway by binding α1-acid glycoproteins and inhibiting the secretion of TNF-α. Studies have shown that TNF-α is strongly positive in macrophages and lymphocytes in CCS patients[25]. In fact, CCS could be characterized as an immune disorder syndrome mediated by IgG4 plasma cells[26]. Previous studies have reported the effect of thalidomide on hormone and immunosuppressant treatment of IgG4-related diseases. Therefore, we speculated that thalidomide, an immunosuppressant, may be effective in the treatment of CCS. At the same time,
compared with hormones, thalidomide acts faster and presents a lower risk of causing infertility. Its use also allows for avoiding other side effects such as osteoporosis, ischemic osteonecrosis, and peptic ulcer caused by hormones. Therefore, we chose thalidomide for its immunomodulatory properties. The long-term follow-up results showed that after taking thalidomide, the clinical symptoms of CCS were quickly relieved, could be maintained for a long time, had only a small economic burden, and were effective and convenient.

CCS prognosis is generally poor. If there is no treatment or treatment delay, the mortality rate of CCS can be as high as 55%. Malnutrition, hypoproteinemia, repeated infection, sepsis, heart failure, and gastrointestinal bleeding are the common causes of death from the disease[26]. Patients with this disease also bear the risk of malignant tumors. For example, intestinal polyps can be adenomatous polyps and serrated adenomas, both of which are precancerous lesions of colorectal cancer. Therefore, regular
monitoring and follow-up are required during the treatment of CCS. If polyps that cannot be subsided by drug administration are found, they need to be removed under endoscopy in time. Experts generally believe that endoscopic monitoring should be carried out every 6-12 mo in order to reduce the mortality rate due to CCS. The patient, in this case, was followed up regularly. Polyps that had not subsided with thalidomide treatment during the follow-up period were timely combined with endoscopic resection, and the postoperative pathological examination was atypical hyperplasia, suggesting that we could early identify precancerous lesions, reduce the risk of polyp malignancies, and obtain a good prognosis.

Our case report is limited to only one patient, and the follow-up time has not been long enough to provide meaningful statistical results. The benefit of thalidomide combined with endoscopy in the treatment of CCS has not been confirmed using a larger sample. Therefore, further clinical studies are needed to determine the dose and duration of treatment and evaluate the long-term efficacy and side effects of thalidomide.

CONCLUSION

At present, the etiology, pathogenesis, and reasonable treatment plan of CCS disease are still in the exploratory stage. The clinical data, diagnosis, and treatment of thalidomide combined with endoscopic therapy in this patient with CCS suggest that thalidomide may be an effective treatment for CCS and thus provide a reference for clinicians.

ACKNOWLEDGEMENTS

We would like to thank the patients and the members of the team for their participation in this study.

FOOTNOTES

Author contributions: Rong JM and Shi ML contributed to manuscript writing and editing, and data collection; Niu JK and Luo J helped revise the manuscript; Miao YL reviewed and revised the entire manuscript; all authors read and approved the final manuscript.

Supported by National Natural Science Foundation of China, No. 82170550.

Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.

Conflict-of-interest statement: The authors have nothing to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Jia-Mei Rong 0000-0002-8549-6978; Jun-Kun Niu 0000-0001-9458-0138; Juan Luo 0000-0001-8400-2246; Ying-Lei Miao 0000-0002-5911-1165.

S-Editor: Wang DM
L-Editor: A
P-Editor: Wang DM

REFERENCES

1 CRONKHITE LW Jr, CANADA WJ. Generalized gastrointestinal polyposis; an unusual syndrome of polyposis, pigmentation, alopecia and onychotrophia. N Engl J Med 1955; 252: 1011-1015 [PMID: 14383952 DOI: 10.1056/NEJM195506162522401]
2 Vashistha N, Chakravarty S, Singhal D. Cronkhite-Canada syndrome. Gastrointest Endosc. 2017; 86: 922-923 [PMID:
Rong JM et al. Thalidomide in the treatment of CCS

1. Oba MS, Murakami Y, Nishiwaki Y, Asakura K, Ohfuji S, Fukushima W, Nakamura Y, Suzuki Y. Estimated Prevalence of Cronkhite-Canada Syndrome, Chronic Enteropathy Associated With SLCO2A1 Gene, and Intestinal Behçet's Disease in Japan in 2017: A Nationwide Survey. J Epidemiol 2021; 31: 139-144 [PMID: 32092751 DOI: 10.2188/jea.JE20190349]

2. Watanabe C, Komoto S, Tomita K, Hokari R, Tanaka M, Hirata I, Hibi T, Kaunzid JT, Miura S. Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite-Canada syndrome: a Japanese nationwide survey. J Gastroenterol 2016; 51: 327-336 [PMID: 26216651 DOI: 10.1007/s00535-015-1107-7]

3. Chakrabarti S. Cronkhite-Canada Syndrome (CCS)-A Rare Case Report. J Clin Diagn Res 2015; 9: OD08-OD09 [PMID: 25954566 DOI: 10.7860/JCDR/2015/11919.5700]

4. Lu Y, Huang F, Wang Y, Zhou J, Zhao Q, Liu L. Clinical and Endoscopic Characteristics of Chinese Cronkhite-Canada Syndrome Patients: A Retrospective Study of 103 Cases. Dig Dis 2021; 39: 488-495 [PMID: 33440392 DOI: 10.1159/000514354]

5. Takeuchi Y, Yoshikawa M, Tsukamoto N, Shiroi A, Hoshida Y, Enomoto Y, Kinuma T, Yamamoto K, Shikihi K, Kikuchi E, Fukui H. Cronkhite-Canada syndrome with colon cancer, portal thrombosis, high titer of antinuclear antibodies, and membranous glomerulonephritis. J Gastroenterol 2003; 38: 791-795 [PMID: 14505136 DOI: 10.1007/s00535-002-1148-6]

6. Ward EM, Wolfson HC. Pharmacological management of Cronkhite-Canada syndrome. Expert Opin Pharmacother 2003; 4: 385-389 [PMID: 12614190 DOI: 10.1517/14656566.4.3.385]

7. Firth C, Harris LA, Smith ML, Thomas LF. A Case Report of Cronkhite-Canada Syndrome Complicated by Membranous Nephropathy. Case Rep Nephrol Dial 2018; 8: 261-267 [PMID: 30643791 DOI: 10.1016/j.cjcneph.2014-202488]

8. Slavik T, Montgomery EA. Cronkhite-Canada syndrome six decades on: the many faces of an enigmatic disease. J Clin Pathol 2014; 67: 891-897 [PMID: 24994091 DOI: 10.1136/jclinpath-2014-204026]

9. She Q, Jiang JX, Si XM, Tian XY, Shi RH, Zhang GX. A severe course of Cronkhite-Canada syndrome and the review of clinical features and therapy in 49 Chinese patients. Turk J Gastroenterol 2013; 24: 277-285 [PMID: 24226722 DOI: 10.4318/tjg.2013.0527]

10. Daniel ES, Ludwig SL, Lewin KJ, Ruprecht RM, Rajacich GM, Schwabe AD. The Cronkhite-Canada Syndrome. An analysis of clinical and pathologic features and therapy in 55 patients. Medicine (Baltimore) 1982; 61: 293-309 [PMID: 7109958]

11. Kim SY, Shin J, Park JS, Cha B, Seo Y, Park SH, Lee JH, Kim JS, Kwon G. The first report on effect of fecal microbiota transplantation as a complementary treatment in a patient with steroid-refractory Cronkhite-Canada syndrome: A case report. Medicine (Baltimore) 2022; 101: e29135 [PMID: 35357354 DOI: 10.1097/MD.0000000000029135]

12. Le KA, Li Y, Xu X, Yang W, Liu T, Zhao X, Tang YG, Cai D, Go VL, Pandol S, Hui H. Alterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetic patients in Southern China population. Front Physiol 2012; 3: 496 [PMID: 23386831 DOI: 10.3389/physiol.2012.00496]

13. Nagy A, Tóth L, Theisz J, Bajkó N, Zolnai Z, Varga M, Igaz I. Cronkhite-Canada syndrome. Orv Hetil 2021; 162: 432-438 [PMID: 33714942 DOI: 10.1556/650.2021.32055]

14. Okamoto K, Isomoto H, Shikawa S, Nishiyama H, Ito M, Kohno S. A case of Cronkhite-Canada syndrome: remission after treatment with anti-Helicobacter pylori regimen. Digestion 2008; 78: 82-87 [PMID: 18948692 DOI: 10.1159/000163534]

15. Sweetser S, Alexander GL, Boardman LA. A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps. Nat Rev Gastroenterol Hepatol 2018; 10: 460-464 [PMID: 29628344 DOI: 10.1038/nrgastro.2010.112]

16. Watanabe D, Ooi M, Hoshi N, Kohashi M, Yoshie T, Ikekara N, Yoshida M, Yanagita E, Yamasaki T, Azuma T. Successful treatment of Cronkhite-Canada syndrome using anti-tumor necrosis factor antibody therapy. Endoscopy 2014; 46 Suppl 1 UCTN: E476-E477 [PMID: 25314205 DOI: 10.1055/s-0034-1377539]

17. Yu X, Wang C, Wang M, Wu Y, Zhang Y, Liang Q, Chen L. Cronkhite-Canada syndrome: a retrospective analysis of four cases at a single medical center. Scand J Gastroenterol 2022; 57: 958-964 [PMID: 35289240 DOI: 10.1080/03655521.2022.2048885]

18. Liu S, You Y, Ruan G, Zhou L, Chen D, Wu D, Yan X, Zhang L, Zhou W, Li J, Qian J. The Long-Term Clinical and Endoscopic Outcomes of Cronkhite-Canada Syndrome. Clin Transl Gastroenterol 2020; 11: e00167 [PMID: 32352683 DOI: 10.14309/ctg.000000000000167]

19. Tjiu JW, Hsiao CH, Tsai TF. Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment. Br J Dermatol 2003; 148: 1060-1061 [PMID: 12786846 DOI: 10.1046/j.1365-2133.2003.05311.x]

20. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 2004; 145: 856-857 [PMID: 15580219 DOI: 10.1016/j.peds.2004.08.020]

21. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol 2005; 52: 500-508 [PMID: 15761429 DOI: 10.1016/j.jaad.2004.10.863]

22. Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41: 1079-1093 [PMID: 25858208 DOI: 10.1111/apt.13181]

23. Martinek J, Chvatalova T, Zavada F, Vankova P, Tuckova I, Zavoral M. A fulminating course of Cronkhite-Canada syndrome. Endoscopy 2010; 42 Suppl 2: E530-E531 [PMID: 21170844 DOI: 10.1055/s-0030-1256003]

24. Sweetser S, Ahlquist DA, Osborn NK, Sanderson SO, Smyrk TC, Chari ST, Boardman LA. Clinicopathologic features and treatment outcomes in Cronkhite-Canada syndrome: support for autoimmunity. Dig Dis Sci 2012; 57: 496-502 [PMID: 21881972 DOI: 10.1007/s10620-011-1874-9]
